Hourglass Capital’s Biogen BIIB Stock Holding History

Hourglass Capital’s Portfolio BIIB Stock Details BIIB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-17,550	Closed	-$3.09M	–	135
2025 Q4	$3.09M	Sell	17,550 -420	-2%	-$68.6K	0.67%	58
2025 Q3	$2.52M	Hold	17,970	–	–	0.57%	63
2025 Q2	$2.26M	Buy	+17,970	New	+$2.24M	0.56%	61

Other funds holding BIIB

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Hourglass Capital's BIIB Position: Q1 2026 in Review

Hourglass Capital sold out of Biogen (BIIB) in Q1 2026, closing a stake of 17,550 shares — an estimated $3.09M sold.

Hourglass Capital first reported a position in BIIB in Q2 2025 and held it in 3 quarters. The position peaked at $3.09M in Q4 2025. 1,002 funds tracked by Wall St. Rank hold BIIB as of Q1 2026.

Hourglass Capital reported no remaining Biogen position as of Q1 2026 after selling out during the quarter.
Hourglass Capital sold 17,550 Biogen shares in Q1 2026, an estimated $3.09M.
Hourglass Capital first reported a position in Biogen in Q2 2025 and held it in 3 quarters.
Hourglass Capital's Biogen position peaked at $3.09M in Q4 2025.
1,002 funds tracked by Wall St. Rank held Biogen as of Q1 2026.

Based on Hourglass Capital's 13F filing for Q1 2026, filed 4 May 2026.